Table 1.
Patient and tumor characteristics in the ITT population
| PTX (n = 47) | PWI (n = 46) | PTI (n = 48) | |
|---|---|---|---|
| Age (years) | |||
| Median | 50 | 49 | 49 |
| Min:Max | 29:73 | 27:78 | 30:75 |
| ECOG performance status [n (%)] | |||
| 0 | 44 (94 %) | 44 (96 %) | 46 (96 %) |
| 1 | 3 (6 %) | 2 (4 %) | 2 (4 %) |
| Menopausal status [n (%)] | |||
| Premenopausal | 20 (43 %) | 27 (59 %) | 26 (54 %) |
| Postmenopausal | 27 (57 %) | 19 (41 %) | 22 (46 %) |
| Stage at initial diagnosis [n (%)] | |||
| IIA | 26 (55 %) | 24 (52 %) | 25 (52 %) |
| IIB | 15 (32 %) | 15 (33 %) | 17 (35 %) |
| IIIA | 6 (13 %) | 5 (11 %) | 6 (13 %) |
| IIIB | 0 | 1 (2 %) | 0 |
| IIIC | 0 | 1 (2 %) | 0 |
| Axillary nodal involvement | |||
| No | 27 (57 %) | 26 (57 %) | 28 (58 %) |
| Yes | 20 (43 %) | 20 (44 %) | 20 (42 %) |
| Tumor size | |||
| ≤5 cm | 42 (89 %) | 42 (91 %) | 42 (88 %) |
| >5 cm | 5 (11 %) | 4 (9 %) | 6 (13 %) |
| ER/PgR/HER2 statusa,b [n (%)] | |||
| Triple negative | 47 (100 %) | 46 (100 %) | 48 (100 %) |
| ER [n (%)] | |||
| <10 % | 47 (100 %) | 46 (100 %) | 48 (100 %) |
| ≤1 % | 46 (98 %) | 39 (85 %) | 42 (88 %) |
a
ER- and PR-negative <10 % IHC or <10 fmol/mg protein by biochemistry
b
HER2 negative non-overexpressing by IHC (negative) or IHC (equivocal) and fluorescence in situ hybridization (FISH) negative